You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Low-Cost, High-Performance Colloidal Quantum Dot MWIR Focal Plane Array
SBC: SIVANANTHAN LABORATORIES, INC. Topic: ST13B002The primary goal of this proposed effort is to develop mid-wavelength infrared (MWIR) colloidal quantum dot (CQD)-based focal plane arrays (FPAs) to significantly reduce the cost of MWIR photon imagers. In order to realize this goal, it will first be nec
STTR Phase I 2014 Department of DefenseDefense Advanced Research Projects Agency -
Data-Parallel Analytics on Graphics Processing Units (GPUs)
SBC: SYSTAP, LLC Topic: ST13B004The proposed effort will extend existing proofs of concept and advanced research systems to: (a) provide an efficient, low-level, data-parallel runtime for graph processing on GPUs; (b) provide a high-level abstraction for writing graph analytics that are
STTR Phase I 2014 Department of DefenseDefense Advanced Research Projects Agency -
Data-Parallel Analytics on Graphics Processing Units (GPUs)
SBC: ANACONDA, INC Topic: ST13B004This proposal aims to show the feasibility of designing a high-level data-parallel language extension to Python on graphics processing units (GPUs). This language extension cooperates with the CPython implementation and uses Python syntax for describing
STTR Phase I 2014 Department of DefenseDefense Advanced Research Projects Agency -
New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cyto
SBC: Nirvana Sciences, Inc. Topic: NIAIDDESCRIPTION (provided by applicant): Polychromatic flow cytometry [FC] is one of the most powerful analytical techniques routinely used in immunology. Flow cytometry plays a critical role in several growing clinical applications: leukemia and lymphoma immunophenotyping for diagnosis and sub-categorization (now using 8-10 colors); in CD4/CD8 measurement in HIV-positive patients; and in HLA typing f ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Ex vivo purging strategy for treatment of multiple myeloma
SBC: DNATRIX INC Topic: NCIDESCRIPTION (provided by applicant): The ultimate goal of this application is to develop a novel ex vivo purging method using myxoma virus (MYXV), a rabbit-specific poxvirus, to improve the clinical outcomes in treatment of multiple myeloma (MM). MM is aclonal plasma cell malignancy that has to date resisted essentially all therapeutic strategies. Currently, the standard of care for patients wit ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics
SBC: PPI PHARMACEUTICALS, LLC Topic: NCIDESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease
SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC. Topic: NIAAbstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Removal of Amyloid-beta Peptides from the Alzheimer's Brain
SBC: WE BIOSCIENCES, LLC Topic: NIADESCRIPTION (provided by applicant): As the Alzheimer's disease (AD) population is growing rapidly, currently there are no cure treatments. The goal of this resubmitted STTR proposal is to conduct a preclinical study with pramlintide to prove a potential treatment for AD. We have revised the proposal significantly according to the reviewers' comments. Pramlintide is an FDA approved drug ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Topically-delivered Targeted Gene Suppression of Immune Activation in Psoriasis
SBC: Exicure, Inc. Topic: NIAMSDESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized nanoparticles can have either DNA or RNA shells, and are less than 50 nm in hydrodynamic diameter. SNA co ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Engineering Cytolytic Effectors to Eliminate Virus-Infected and Cancer Cells
SBC: IMMUVEN, INC. Topic: NCIProject Summary The goal of this STTR grant application is to engineer powerful NK cell-based cytolytic effector cells for therapeutic applications. The cells will combine the selectivity and specificity of T cells and the ability of NK cells to mediate effective cytolytic activity against a wide spectrum of aberrant cells, including those with impaired adhesion properties. To achieve this goal we ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health